Daijiworld Media Network – New Delhi

New Delhi, Mar 17: Scientists are testing a breakthrough ‘fridge-free’ vaccine that could eliminate the need for cold storage, potentially transforming global immunisation efforts, especially in remote and low-resource regions.

Most vaccines today depend on the “cold chain”, requiring storage between 2°C and 8°C to remain effective. This system relies on continuous refrigeration, insulated transport, and stable electricity—posing major logistical and cost challenges. Experts estimate that up to half of vaccines globally may be wasted due to temperature-control failures during storage and transport.

The new vaccine, SPVX02, developed by UK-based biotech firm Stablepharma with support from the UK Health Security Agency, targets tetanus and diphtheria. Early results from a Phase I human trial indicate that the vaccine can remain stable at temperatures around 30°C for up to two years, raising hopes for immunisation programmes that do not rely on refrigeration.

The trial, conducted at the Vaccine Development and Evaluation Centre in the United Kingdom, tested the vaccine on healthy volunteers to assess safety and immune response. While Phase I trials primarily focus on safety, researchers say the initial findings are encouraging, and further large-scale trials will determine its effectiveness compared to conventional vaccines.

Public health experts believe such thermostable vaccines could significantly improve access in low- and middle-income countries, where maintaining cold chain infrastructure is difficult. Failures in refrigeration due to power outages, equipment breakdowns, or transport delays often disrupt vaccine delivery, particularly in rural areas.

For India, which runs one of the world’s largest immunisation drives under the Universal Immunisation Programme, such technology could be a game-changer. Reducing dependence on cold storage could simplify vaccine delivery across diverse climates and remote regions, cut costs, and minimise wastage.

Experts highlight multiple benefits beyond logistics, including reduced vaccine losses, lower infrastructure costs, faster deployment during emergencies, and environmental gains from decreased energy consumption.

However, the vaccine must still undergo further clinical trials before widespread use. If successful, scientists believe the same technology could be adapted for other vaccines and temperature-sensitive medicines, marking a significant step forward in global healthcare.